NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

Search

Coloplast A-S (Class B)

Închisă

543.8 -0.87

Rezumat

Modificarea prețului

24h

Curent

Minim

540.6

Maxim

547.6

Indicatori cheie

By Trading Economics

Venit

-107M

805M

Vânzări

28M

7B

P/E

Medie Sector

34.873

76.798

EPS

3.88

Randament dividend

4.1

Marjă de profit

11.569

Angajați

16,744

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+11.86% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.10%

2.37%

Statistici piață

By TradingEconomics

Capitalizare de piață

-9.9B

127B

Deschiderea anterioară

544.67

Închiderea anterioară

543.8

Coloplast A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 dec. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec. 2025, 23:51 UTC

Câștiguri

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec. 2025, 23:39 UTC

Principalele dinamici ale pieței

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec. 2025, 21:40 UTC

Câștiguri

Nike Sales Tick Up, But China Weakness Persists

18 dec. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec. 2025, 23:37 UTC

Market Talk
Câștiguri

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec. 2025, 23:00 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec. 2025, 22:58 UTC

Achiziții, Fuziuni, Preluări

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec. 2025, 22:57 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec. 2025, 22:56 UTC

Achiziții, Fuziuni, Preluări

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec. 2025, 22:55 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:59 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 dec. 2025, 21:35 UTC

Câștiguri

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec. 2025, 21:31 UTC

Câștiguri

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev Down 17% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q EPS 53c >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Apparel Rev $3.91B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Equipment Rev $550M >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q N Amer Rev $5.63B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Footwear Rev $7.66B >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dec. 2025, 21:15 UTC

Câștiguri

Nike 2Q Greater China Rev $1.42B >NKE

Comparație

Modificare preț

Coloplast A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

11.86% sus

Prognoză pe 12 luni

Medie 901.38 DKK  11.86%

Maxim 1,056 DKK

Minim 720 DKK

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruColoplast A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

2

Cumpărare

4

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat